Results 71 to 80 of about 14,652 (127)

Efficacy and safety of SGLT2 inhibitor empagliflozin in T2DM with established cardiovascular disease: a systematic review and meta-analysis of RCTs. [PDF]

Ann Med Surg (Lond)
Abunada O, Hassan F, Kumar N, Kumar S, Majeed I, Batra K, Kumar D, Deepika D, Turesh M, Ashraf T, Hyder S, Suresh KN, Kumar L, Kumar S, Kamlesh F, Yusuf SA.   +15 more
europepmc   +1 more source

Expert Opinion of Empagliflozin Positioning in the Current Type 2 Diabetes Mellitus (T2DM) Landscape in Indian Patients. [PDF]

Cureus
Sethi B, Mehta A, Dasgupta A, Chawla M, Deka N, Agarwal N, Mazumder C, Ghosh I, Gala V, Muchhala S, Sonkar A.   +10 more
europepmc   +1 more source

Empagliflozin Perception Mapping Survey. [PDF]

Cureus
Kovil R, Panikar V, Kesavadev J, Tanna S, Nayak K, Punatar D, Purohit L, Kedia AK, Sanghvi A, Jagadeesha A, Chandratre S, Walawalkar S, Patel M, Virmani AK, Mathur G, Mehta KK, Muchhala S, Gala V, Sonkar A.   +18 more
europepmc   +1 more source

Empagliflozin improves beta cell function independently of relief of glucotoxicity in patients with type 2 diabetes: results from a randomised cross-over study with insulin as comparator. [PDF]

Diabetologia
Thirumathyam R, Richter EA, van Hall G, Andersen NR, Madsen PL, Holst JJ, Madsbad S, Jørgensen NB.   +7 more
europepmc   +1 more source

Medication Adherence to Semaglutide versus Empagliflozin in Adults with Type 2 Diabetes: A Retrospective Observational Study in Saudi Arabia. [PDF]

Patient Prefer Adherence
Ali MAS, Amirthalingam P, Alshareef H, Alqifari SF, Elsaid Hamdan AM, Alatawi O, Hakami FAM, Albalawi NS, Aljabri A.   +8 more
europepmc   +1 more source

Effects of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors on Lipid Profiles in Type 2 Diabetes: A Systematic Review. [PDF]

Cureus
Abdalla M, Khamees MES, Gehani AL, Ibrahim AIM, Yousif MY, Kheir N, Mohammed Qasem Alqasem S, Ahmed A.   +7 more
europepmc   +1 more source

Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction. [PDF]

Cardiovasc Diabetol
Nowak-Szwed A, Eyileten C, Wicik Z, Ahmadova S, Palatini J, Siller-Matula J, von Lewinski D, Sourij H, Postula M.   +8 more
europepmc   +1 more source

Carbohydrate antigen 125 (CA125) following acute myocardial infarction: effects of empagliflozin and association with heart failure readouts in the EMMY trial. [PDF]

Sci Rep
Hassan AM, Aziz F, Tripolt NJ, Herrmann M, Sourij H, von Lewinski D.   +5 more
europepmc   +1 more source